Table 1.

Reported odds ratios (RORs) for ocular adverse events with use of immune checkpoint inhibitors (ICIs) in the Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2003 to 2018.

Drug name (s)	Adverse event (s)	Events with specific ICI	RORa
All ICIs of interestb	All adverse events of interestc	113	2.52 (2.06–3.08)
Atezolizumab	All adverse events of interestc	4	3.79 (1.42–10.14)
Atezolizumab	Uveitis	1	4.60 (0.65–32.76)
Atezolizumab	Eye inflammation	3	18.89 (6.07–58.81)
Ipilimumab	All adverse events of interestc	17	2.65 (1.91–3.68)
Ipilimumab	Uveitis	15	10.54 (7.30–15.22)
Ipilimumab	Dry eye	1	0.34 (0.11–1.05)
Ipilimumab	Eye inflammation	1	1.95 (0.73–5.20)
Nivolumab	All adverse events of interestc	68	2.73 (2.09–3.57)
Nivolumab	Uveitis	45	8.73 (6.25–12.20)
Nivolumab	Dry eye	11	0.62 (0.32–1.24)
Nivolumab	Ocular myasthenia	3	22.82 (7.18–72.50)
Nivolumab	Eye inflammation	9	2.68 (1.34–5.36)
Pembrolizumab	All adverse events of interestc	24	2.47 (1.56–3.93)
Pembrolizumab	Uveitis	22	10.80 (6.60–17.68)
Pembrolizumab	Dry eye	1	0.21 (0.03–1.50)
Pembrolizumab	Ocular myasthenia	1	20.17 (2.28–145.20)

ROR: Reported odds ratios; ICI: Immune checkpoint inhibitor.

Drugs with no reported adverse events of interest were not included in the table.

^aRORs with 95% confidence intervals.

^bAll ICIs of interest include: atezolizumab, avelumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab.

^cAll adverse events of interest include uveitis, dry eye, ocular myasthenia and eye inflammation.